The FDA has approved ribociclib combined with aromatase inhibitor therapy for women with metastatic HR-positive, HER2-negative breast cancer. It is the second CDK 4/6 inhibitor approved for these patients, behind palbociclib; a third is under investigation.
http://ift.tt/2oZJfpV
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου